About Dr Peter Surman
Peter leads the scientific direction of Douglas CDMO. He has been with Douglas Pharmaceuticals for more than 28 years, and has led more than 20 products from concept to market in the United States, Europe and Australasia.
His expertise spans softgel and oral formulation development, with a particular focus on improving the bioavailability, stability and shelf life of poorly soluble and unstable compounds. He also guides analytical method development, nitrosamine impurity control and the pharmaceutical quality systems behind every program.
Peter regularly shares his perspective on formulation strategy and dosage form selection, including through Contract Pharma webinars and Outsourced Pharma's Capacity Update events.
His expertise spans softgel and oral formulation development, with a particular focus on improving the bioavailability, stability and shelf life of poorly soluble and unstable compounds. He also guides analytical method development, nitrosamine impurity control and the pharmaceutical quality systems behind every program.
Peter regularly shares his perspective on formulation strategy and dosage form selection, including through Contract Pharma webinars and Outsourced Pharma's Capacity Update events.
Areas of expertise
Insights by Dr Peter Surman
Smart softgels: driving innovation in pharma
Read articleTarget product profiles and Phase I clinical plans: laying the groundwork for success
Read articleThe case for softgels: Addressing stability, shelf-life, and bioavailability issues in pharmaceutical formulation
Read articleDouglas CDMO presents at Outsourced Pharma Capacity Update January 2025
Read articleOutsourced Pharma Capacity Update Partner Week
Read articleWork with Dr Peter Surman’s team
Talk to Douglas CDMO about formulation, development and manufacturing for your molecule.
Get In Touch